La Jolla Pharmaceutical Co represents values of innovation, dedication, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered around advancing healthcare, the company strives to develop and commercialize life-changing therapies for patients in need. La Jolla Pharmaceutical Co is committed to conducting rigorous research, fostering collaborations, and utilizing cutting-edge technology to deliver novel treatment options. By putting patients first and ensuring the highest quality standards, La Jolla Pharmaceutical Co remains at the forefront of delivering transformative healthcare solutions.

La Jolla Pharmaceutical Co is primarily present in the United States.

La Jolla Pharmaceutical Co has achieved several significant milestones. Firstly, the company successfully developed and launched its flagship product, Giapreza, a medication used for the treatment of low blood pressure. This achievement marked a significant breakthrough in the field of critical care medicine. Additionally, La Jolla Pharmaceutical Co obtained the approval from the U.S. Food and Drug Administration (FDA) for Giapreza, further validating its effectiveness and safety. The company has also focused on advancing its research pipeline, conducting clinical trials, and securing partnerships to drive innovation and growth in the pharmaceutical industry. Overall, La Jolla Pharmaceutical Co has demonstrated remarkable progress in developing life-saving treatments and garnering regulatory approvals.

La Jolla Pharmaceutical Co is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for life-threatening diseases. Founded in 1989, La Jolla Pharmaceutical Co has a rich history in advancing medical research and delivering breakthrough treatments to patients. It has a strong portfolio of products targeting conditions like sepsis and specific organ dysfunction. With a commitment to scientific excellence and patient welfare, La Jolla Pharmaceutical Co continues to push the boundaries of healthcare innovation. As a reputable player in the pharmaceutical industry, La Jolla Pharmaceutical Co's dedication to enhancing patient outcomes remains steadfast.

The main competitors of La Jolla Pharmaceutical Co in the market are companies such as Amgen Inc., Gilead Sciences Inc., and Biogen Inc.

La Jolla Pharmaceutical Co is primarily active in the biotechnology industry.

The business model of La Jolla Pharmaceutical Co. revolves around developing and commercializing innovative therapies to improve outcomes in patients suffering from life-threatening diseases. La Jolla Pharmaceutical focuses on the discovery, development, and commercialization of proprietary therapeutics for patients with significant unmet medical needs. The company strives to bring groundbreaking treatments to the market that address critical medical challenges. La Jolla Pharmaceutical Co.'s commitment to research and development, along with strategic partnerships, enables the company to deliver effective solutions and make a meaningful impact on patients' lives.

لا يمكن حساب مضاعف الربحية للسهم لـLa Jolla Pharmaceutical في الوقت الحالي.

لا يمكن حالياً حساب معامل القيمة السوقية إلى العائدات لـ La Jolla Pharmaceutical.

نقاط جودة AlleAktien لـ La Jolla Pharmaceutical هي 3/10.

لا يمكن حالياً حساب الإيرادات لـLa Jolla Pharmaceutical.

لا يمكن حساب الربح لـ La Jolla Pharmaceutical في الوقت الحالي.

La Jolla Pharmaceutical Co is a research-oriented biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for serious diseases. The company is headquartered in San Diego, California. The business model of La Jolla Pharmaceutical Co specializes in the development and marketing of biologic drugs. The company is involved in the following areas: - Development of drugs for serious diseases La Jolla Pharmaceutical Co has focused on the development of drugs for serious diseases such as sepsis, shock, and severe organ dysfunction. The company uses its own proprietary technology platform to develop novel therapeutic antibodies. - Distribution of drugs in the USA La Jolla Pharmaceutical Co is a pharmaceutical company that focuses on the distribution of drugs in the USA. The company has an experienced sales team that is responsible for the distribution of products in the market. The products are distributed directly to hospitals, clinics, and pharmacies as well as through wholesalers. - Research and development of new products La Jolla Pharmaceutical Co invests a significant portion of its revenue from product sales into research and development of new products. The company has a dedicated team of researchers and scientists specializing in the development of new and innovative therapies for serious diseases. The products of La Jolla Pharmaceutical Co include the following: - Giapreza (Angiotensin II injection solution) Giapreza is the main product of La Jolla Pharmaceutical Co. It is an injection solution used for the treatment of patients with severe or life-threatening hypovolemic shock. This condition is characterized by a drop in blood pressure and inadequate blood supply to the heart. - Xerava (Eravacycline injection) Xerava is an antibiotic used for the treatment of severe Gram-negative bacterial infections. - Vabriolix (Croxinjektion) Vabriolix is an antibiotic used for the treatment of nosocomial and complicated urinary tract infections. In summary, La Jolla Pharmaceutical Co is a research-oriented biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for serious diseases. The company has focused on the development of drugs for serious diseases such as sepsis, shock, and severe organ dysfunction. La Jolla Pharmaceutical Co has an experienced sales team responsible for the distribution of products in the market, as well as a dedicated team of researchers and scientists specialized in the development of new and innovative therapies. The products of La Jolla Pharmaceutical Co include antibiotics and injection solutions for the treatment of serious and life-threatening diseases.

يوزع La Jolla Pharmaceutical أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ La Jolla Pharmaceutical في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـLa Jolla Pharmaceutical هو US5034596040.

رمز WKN لـ La Jolla Pharmaceutical هو A1XB6B.

الرمز المُختصر لـ La Jolla Pharmaceutical هو LJPC.

خلال آخر 12 شهراً، دفعت La Jolla Pharmaceutical توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع La Jolla Pharmaceutical خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ La Jolla Pharmaceutical هي .

La Jolla Pharmaceutical يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

La Jolla Pharmaceutical دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

La Jolla Pharmaceutical يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من La Jolla Pharmaceutical المُعلن عنها في ١١‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١١‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١١‏/٨‏/٢٠٢٤.

في العام 2023، وزعت La Jolla Pharmaceutical 0 USD كأرباح أسهم.

يتم توزيع أرباح La Jolla Pharmaceutical بالعملة USD.